Aligos Therapeutics, Inc. announced that the company remains on track to complete all Phase 2-enabling activities in 2023 for ALG-055009, its thyroid hormone receptor beta (THR-ß) drug candidate for nonalcoholic steatohepatitis (NASH). Dr. Blatt will provide a corporate update and discuss the company's entire pipeline, including ALG-055009, the coronavirus protease inhibitor ALG-097558, and Aligos' hepatitis B portfolio, on January 12, 2023, at 10:30 a.m. PT during the 41st Annual JP Morgan Healthcare Conference in San Francisco. Dr. Blatt's presentation will also be posted on the Aligos website at the time of the conference.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.5199 USD | +1.66% |
|
+28.66% | -21.70% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.70% | 40.61M | |
+22.10% | 46.55B | |
+46.45% | 41.84B | |
-3.12% | 40.84B | |
+36.10% | 32.95B | |
-6.30% | 28.27B | |
+18.71% | 27.78B | |
+46.15% | 14.26B | |
+44.52% | 13.69B | |
+0.19% | 12.18B |
- Stock Market
- Equities
- ALGS Stock
- News Aligos Therapeutics, Inc.
- Aligos Therapeutics, Inc. on Track to Complete Phase 2-Enabling Activities in 2023 for its Clinically Validated THR-ß Drug Candidate for NASH, ALG-055009